UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 351

Sortiert nach

Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma In Situ: 15-Year Recurrence Rates and Outcome After a Recurrence, From the EORTC 10853 Randomized Phase III Trial

Journal of clinical oncology, 2013-11, Vol.31 (32), p.4054-4059

2013

Volltextzugriff (PDF)

predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer

Breast cancer research and treatment, 2010-04, Vol.120 (3), p.655-661

2010

Volltextzugriff (PDF)

Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial

The lancet oncology, 2014-11, Vol.15 (12), p.1303-1310

2014

Volltextzugriff (PDF)

Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue

PloS one, 2011-02, Vol.6 (2), p.e17163-e17163

2011

Volltextzugriff (PDF)

Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – The LORD study

European journal of cancer (1990), 2015-08, Vol.51 (12), p.1497-1510

2015

Volltextzugriff (PDF)

Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ

Annals of surgery, 2018-05, Vol.267 (5), p.952-958

2018

Volltextzugriff (PDF)

Marking Axillary Lymph Nodes With Radioactive Iodine Seeds for Axillary Staging After Neoadjuvant Systemic Treatment in Breast Cancer Patients: The MARI Procedure

Annals of surgery, 2015-02, Vol.261 (2), p.378-382

2015

Volltextzugriff (PDF)

Sentinel Node Identification Rate and Nodal Involvement in the EORTC 10981-22023 AMAROS Trial

Annals of surgical oncology, 2010-07, Vol.17 (7), p.1854-1861

2010

Volltextzugriff (PDF)

Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)

JNCI : Journal of the National Cancer Institute, 2018-01, Vol.110 (1), p.40-48

2018

Volltextzugriff (PDF)

Role of Axillary Clearance After a Tumor-Positive Sentinel Node in the Administration of Adjuvant Therapy in Early Breast Cancer

Journal of clinical oncology, 2010-02, Vol.28 (5), p.731-737

2010

Volltextzugriff (PDF)

Micrometastases or Isolated Tumor Cells and the Outcome of Breast Cancer

The New England journal of medicine, 2009-08, Vol.361 (7), p.653-663

2009

Volltextzugriff (PDF)

Impact of mammographic screening on the detection of good and poor prognosis breast cancers

Breast cancer research and treatment, 2011-12, Vol.130 (3), p.725-734

2011

Volltextzugriff (PDF)

Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma-In-Situ: Ten-Year Results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853—A Study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group

Journal of clinical oncology, 2006-07, Vol.24 (21), p.3381-3387

2006

Volltextzugriff (PDF)

Cardiovascular Disease Risk in a Large, Population-Based Cohort of Breast Cancer Survivors

International journal of radiation oncology, biology, physics, 2016-04, Vol.94 (5), p.1061-1072

2016

Volltextzugriff (PDF)

Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial

Journal of clinical oncology, 2022-04, Vol.40 (12), p.1335-1345

2022

Volltextzugriff (PDF)

Contribution of SPECT/CT for sentinel node localization in patients with ipsilateral breast cancer relapse

European journal of nuclear medicine and molecular imaging, 2017-04, Vol.44 (4), p.630-637

2017

Volltextzugriff (PDF)

Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study

Breast cancer research and treatment, 2021, Vol.185 (1), p.205-214

2021

Volltextzugriff (PDF)

Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS)

Breast (Edinburgh), 2017-02, Vol.31, p.274-283

2017

Volltextzugriff (PDF)

70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

Breast cancer research and treatment, 2010-02, Vol.119 (3), p.551-558

2010

Volltextzugriff (PDF)

Sentinel Node Biopsy: Interpretation and Management of Patients With Immunohistochemistry-Positive Sentinel Nodes and Those With Micrometastases

Journal of clinical oncology, 2008-02, Vol.26 (5), p.698-702

Rutgers, Emiel J T

2008

Volltextzugriff (PDF)

Locoregional Breast Cancer Recurrence in the European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT Trial: Analysis of Risk Factors Including the 70-Gene Signature

Journal of clinical oncology, 2024-04, Vol.42 (10), p.1124

2024

Volltextzugriff (PDF)

Is prophylactic mastectomy justified in women without BRCA mutation?

Breast (Edinburgh), 2019-11, Vol.48 Suppl 1, p.S62-S64

Rutgers, Emiel J T

2019

Volltextzugriff (PDF)

1 – 25 von 351

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(339)
Mit Volltextzugriff
(332)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma In Situ: 15-Year Recurrence Rates and Outcome After a Recurrence, From the EORTC 10853 Randomized Phase III Trial

predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer

Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial

Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue

Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – The LORD study

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial

Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ

Marking Axillary Lymph Nodes With Radioactive Iodine Seeds for Axillary Staging After Neoadjuvant Systemic Treatment in Breast Cancer Patients: The MARI Procedure

Sentinel Node Identification Rate and Nodal Involvement in the EORTC 10981-22023 AMAROS Trial

Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)

Role of Axillary Clearance After a Tumor-Positive Sentinel Node in the Administration of Adjuvant Therapy in Early Breast Cancer

Micrometastases or Isolated Tumor Cells and the Outcome of Breast Cancer

MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial

Impact of mammographic screening on the detection of good and poor prognosis breast cancers

Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma-In-Situ: Ten-Year Results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853—A Study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group

Cardiovascular Disease Risk in a Large, Population-Based Cohort of Breast Cancer Survivors

Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial

Contribution of SPECT/CT for sentinel node localization in patients with ipsilateral breast cancer relapse

Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study

Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS)

70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

Sentinel Node Biopsy: Interpretation and Management of Patients With Immunohistochemistry-Positive Sentinel Nodes and Those With Micrometastases

Locoregional Breast Cancer Recurrence in the European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT Trial: Analysis of Risk Factors Including the 70-Gene Signature

Is prophylactic mastectomy justified in women without BRCA mutation?

Suchergebnisse filtern